Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma
oleh: Xi Zhang, Liqiong Wang, Shu Chen, Peng Huang, Lan Ma, Hui Ding, Basappa Basappa, Tao Zhu, Peter E. Lobie, Vijay Pandey
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-07-01 |
Deskripsi
Zhang et al. test the therapeutic potential of an inhibitor of BAD phosphorylation, NPB, in epithelial ovarian cancer. The authors show that the small molecule synergises with PARP inhibition to kill patient-derived ovarian cancer organoids and suppress the growth of xenograft tumours, including a cisplatin-resistant model.